WeiXu
Department of Dermatology, Beijing Friendship Hospital, Capital Medical University
Title: Efficacy and safety of compound glycyrrhizin capsules in patients with chronic eczema: A multi-center, randomized, double-blind, placebo-controlled study
Biography
Biography: WeiXu
Abstract
This multi-center, 1: 1randomized, double-blind, placebo-controlled study aimed to evaluate the efficacy and safety of the traditional Chinese medicine oral compound glycyrrhizin (OCG) for adult chronic eczema. Methods: A total of 199 patients were equally randomized to the treated group receiving OCG capsules 3 times daily 75mg/time and mometasone furoate 0.1% ointment once daily for 28 days and the placebo group receiving placebo and the topical cream. The eczema area and severity index (EASI) score, the Investigator’s Global Assessment (IGA) score, and visual analogue scale score of itching were evaluated. Results: On day 28 of the treatment, compared with the placebo group, the treated group showed significantly greater extent of reductions in the absolute EASI (-7.39±1.71 vs. -6.64±1.75, P=0.003) and IGA (-2.63 ± 0.75 vs. -2.34±0.70, P<0.05) from the corresponding baselines and had significantly higher proportions of patients achieving EASI 50 (96.8% vs. 87.9%, P=0.021) and EASI 75 (47.9% vs. 21.2%, P<0.001), patients achieving IGA scores of clear (0) or almost clear (1) on day 28 (93.5% vs. 79.4%, P=0.005), and patients showing pruritus attenuation ( 94.7% vs. 83.8%, P=0.016). The treated group showed significantly less recurrence than the placebo group (3.19% vs. 12.12%, P=0.021). Adverse events occurred in 11 patients including 3 in the placebo group (3.0%) and 8 in the treated group (8.5%, P>0.05). Conclusion: OCG capsules combined with topical cream mometasone furoate 0.1% ointment is an effective and safe therapy for adult chronic eczema. Compound glycyrrhizin could be a promising steroid sparing agent for clinical application.